ProMetic Life Sciences Inc. (TSE:PLI) insider Bruce Pritchard sold 84,594 shares of the stock in a transaction on Friday, August 25th. The shares were sold at an average price of C$1.15, for a total value of C$97,283.10.

Bruce Pritchard also recently made the following trade(s):

  • On Tuesday, August 22nd, Bruce Pritchard purchased 48,400 shares of ProMetic Life Sciences stock. The stock was bought at an average price of C$1.30 per share, with a total value of C$62,920.00.

Shares of ProMetic Life Sciences Inc. (TSE PLI) traded down 4.29% during midday trading on Friday, reaching $1.56. The company’s stock had a trading volume of 774,179 shares. ProMetic Life Sciences Inc. has a 12 month low of $1.12 and a 12 month high of $3.24. The company’s market cap is $1.10 billion. The stock has a 50-day moving average of $1.47 and a 200 day moving average of $1.94.

TRADEMARK VIOLATION NOTICE: “ProMetic Life Sciences Inc. (PLI) Insider Bruce Pritchard Sells 84,594 Shares” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/prometic-life-sciences-inc-pli-insider-bruce-pritchard-sells-84594-shares/1536705.html.

A number of equities analysts recently weighed in on PLI shares. Royal Bank Of Canada reiterated an “outperform” rating on shares of ProMetic Life Sciences in a research report on Wednesday, May 24th. Canaccord Genuity decreased their price target on ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating for the company in a research report on Monday, June 19th. Scotiabank decreased their price target on ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating for the company in a research report on Friday, July 7th. National Bank Financial increased their price target on ProMetic Life Sciences from C$2.00 to C$2.50 in a research report on Wednesday. Finally, TD Securities decreased their price target on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating for the company in a research report on Wednesday, August 16th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of C$3.60.

ProMetic Life Sciences Company Profile

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Insider Buying and Selling by Quarter for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.